Aptadir Therapeutics Closes €40 Million Seed Round
4BIO Capital leads a €40 million seed round in Aptadir Therapeutics to advance RNA inhibitor therapies, starting with lead candidate CAP1-FMR1 for Fragile X syndrome.
Topic
Aptadir Therapeutics
Topic
Aptadir Therapeutics
CE-Ventures Backs Aptadir Therapeutics in €40 Million Seed Round
CE-Ventures has backed Aptadir Therapeutics in a €40 million seed round, ranking among Europe's largest biotech seed financings a…